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Background: Few reports have studied the possible 
association between the haptoglobin (Hp) genotype and the 
risk of diabetic nephropathy (DN) in type 1 diabetes (T1D), 
with conflicting results to date. Aims: To study whether 
the 2-2 Hp genotype is associated with an increased risk of 
overt DN in a Spanish population with T1D. Methods: We 
performed a case-control study in a Spanish population. 
CASES: T1D patients with end-stage renal disease (stage 5 
of NKF-KDOQI), awaiting reno-pancreatic transplantation 
or having already been transplanted (reno-pancreatic or 
renal alone). CONTROLS: T1D patients, matched for sex and 
time of diabetes evolution, with preserved renal function 
and normal urinary albumin excretion. Hp genotyping was 
done using polymerase chain reaction and electrophoresis. 
Results: We included 57 cases and 57 controls in the study. 
There were no statistically significant differences in gender 
(70% vs. 61% males, p=1.0) or the duration of diabetes 
(23.0±6.7 vs. 20.8±9.3 years; p=0.1), although the age 
of onset of diabetes was lower in the cases (14.1±6.8 vs. 
17.7±10.1 years, p=0.03). The frequency of genotypes 1-1, 
1-2 and 2-2 was 19.3%, 42.1% and 38.6% in cases and 
17.5%, 49.1% and 33.4% in controls, respectively, with 
no statistically significant differences between groups 
(p=0.8). Conditional logistic regression analysis showed no 
significant association between genotype 2-2 of Hp and the 
development of DN (OR 1.14, CI 0.52-2.52). Conclusions: In 
our sample of a Spanish population with T1D, no association 
was found between the Hp genotype and risk of overt DN.
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Genotipo de la haptoglobina y riesgo de nefropatía 
diabética en pacientes con diabetes mellitus tipo 1: estudio 
en población española
RESUMEN
Antecedentes: Pocos trabajos han estudiado la asociación en-
tre el genotipo de la haptoglobina (Hp) y el riesgo de nefropa-
tía diabética (ND) en pacientes con diabetes tipo 1 (DM1), con 
resultados contradictorios hasta ahora. Objetivos: Estudiar si el 
genotipo 2-2 de Hp se asocia a un incremento del riesgo de ND 
en población española con DM1. Métodos: Se diseñó un estu-
dio de casos y controles. CASOS: pacientes con DM1 y enfer-
medad renal crónica estadio 5 de la NKF-KDOQI, en espera de 
trasplante reno-pancreático o que han sido trasplantados (re-
no-pancreático o renal aislado). CONTROLES: pacientes con DM1, 
apareados por sexo y tiempo de evolución de la diabetes, con 
función renal y excreción urinaria de albúmina normales. El 
genotipo de Hp se realizó mediante reacción en cadena de la 
polimerasa y electroforesis. Resultados: Incluimos 57 casos y 
57 controles, sin diferencias estadísticamente significativas en 
el sexo (70 % frente a 61 % varones, p = 1,0) o duración de la 
diabetes (23,0 ± 6,7 frente a 20,8 ± 9,3 años; p = 0,1), aunque la 
edad de inicio de la diabetes fue menor en los casos (14,1 ± 6,8 
frente a 17,7 ± 10,1 años, p = 0,03). La frecuencia de genotipos 
1-1, 1-2 y 2-2 fue de 19,3 %, 42,1 % y 38,6 % en los casos y de 
17,5 %, 49,1 % y 33,4 % en los controles, respectivamente, sin 
diferencias significativas (p = 0,8). El análisis de regresión logís-
tica condicional no mostró asociación entre el genotipo 2-2 de 
Hp y el desarrollo de ND (OR 1,14, IC 0,52-2,52). Conclusiones: 
En nuestra muestra de población española con DM1, no se ha 
hallado asociación entre el genotipo de Hp y el riesgo de ND.
Palabras clave: Diabetes mellitus tipo 1. Nefropatía diabética. 
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INTRODUCTION
 
Haptoglobin (Hp) is a protein that acts as an antioxidant 
due to its ability to combine with haemoglobin and prevent 
tissue damage caused by free haemoglobin. The Hp gene 
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of DNA supplied by Biobank via polymerase chain reaction 
following the protocol of Koch et al.12.
The study protocol was performed in agreement with the 
Declaration of Helsinki and was approved by the Ethics 
Committee of both Hospital Clínic i Universitari de Barcelona 
and Biobank. Informed consent of the subjects of the study 
was obtained.
Statistical analysis was carried out using the STATA.11 
statistical package. Numerical variables are shown as means 
and standard deviations for the continuous variables, and 
as a number and percentage for categorical variables. The 
Student’s t-test was used for the comparison of continuous 
variables and the chi-squared test for categorical variables. 
Logistic regression models were constructed in order to 
study the association between the genotype 2-2 of Hp and 
DN. The Hardy-Weinberg equilibrium study for the genotype 
of Hp was analysed with 1 degree of freedom. Statistical 




114 patients were included in the study, 57 cases and 
57 controls. There were no statistically significant differences 
in sex (70 % vs. 61 % males, P=1.0) or the duration of 
diabetes (23.0 ± 6.7 vs. 20.8 ± 9.3 years, P=.1). However, 
the cases were older (44.9 ± 8.6 vs. 40.9 ± 9.5 years, P=.02) 
and the age at onset of diabetes was lower (14.1 ± 6.8 vs. 
17.7 ± 10.1 years, P=.03).
The distribution of genotypes in our sample was in Hardy-
Weinberg equilibrium. The prevalence of the genotype 
1-1, 2-1 and 2-2 of Hp was 19.3 %, 42.1 % and 38.6 % 
in cases, and 17.5 %, 49.1 % and 33.4 % in controls, 
respectively. There were no differences in the frequency 
of the different genotypes or in the frequency of the 
different alleles between cases and controls (Table 1). The 
logistic regression study, including sex and the time of 
T1D evolution as covariables in the model, did not show 
a statistically significant association between the genotype 
2-2 of Hp and the development of DN (odds ratio 1.14, 




In this case-control study in a Spanish population, we did not 
find a association between the Hp genotype and the presence 
of DN in patients with T1D, despite careful patient selection, 
representing the extremes of the DN spectrum with the same 
time of diabetes evolution.
The contribution of the genotype of Hp to the risk of CVD 
has been analysed in various longitudinal studies, relating 
is polymorphic, with two types of alleles, named 1 and 2, 
resulting in three potential genotypes of Hp: Hp 1-1, Hp 2-1 
and Hp 2-2.1 The protein derived from allele 2 of Hp provides 
less antioxidant activity than the protein of allele 1.1,2
There is increasing evidence in medical literature of the 
association between the genotype of Hp and cardiovascular 
disease (CVD).3 In this respect, various longitudinal 
epidemiological studies have found a risk of CVD 2 to 8 
times greater in patients with diabetes mellitus with the Hp 
genotype 2-2, both in type 1 diabetes mellitus (T1D) as well 
as in type 2 (T2D).4-7
The association between the Hp genotype and microvascular 
complications in diabetes has been less studied. Until now, 
few studies have focused on the implications of Hp in the 
risk of diabetic nephropathy (DN), using heterogeneous 
populations of patients with T1D, with contradictory results 
to date.8-11
In light of these findings, the objective of our study is to 
investigate whether the genotype 2-2 of Hp is associated with 




A case-control study was designed for a Spanish population. 
All the patients were selected from the Biobank database 
(DNA bank) from the Institut d’Investigacions Biomèdiques 
August Pi i Sunyer (IDIBAPS) and from the Spanish 
Biomedical Research Centre in Diabetes and Associated 
Metabolic Disorders (CIBERDEM), a technical and scientific 
infrastructure that coordinates the obtaining, processing, 
storage and provision of biological samples (http://www.
clinicbiobanc.org/en_index.html). The cases were defined as 
all the patients registered in the Biobank with T1D and stage 5 
chronic renal failure of the National Kidney Foundation 
Kidney Disease Outcomes Quality Initiative, awaiting reno-
pancreatic transplantation or having already been transplanted 
(reno-pancreatic or renal alone).
The controls were defined as patients with T1D and preserved 
renal function (estimated glomerular filtration [eGFR] 
> 90ml/min/1.73m2) and normal urinary excretion of albumin, 
paired with the cases by sex and time of diabetes evolution 
(matching by frequency). T1D evolution time was defined 
as the years between the diagnosis of diabetes and the date 
on reaching an eGFR < 15ml/min/1.73m2 (for the cases) and 
between the diagnosis of the illness and the entry date into the 
database of Biobank (for the controls).
The clinical data collected were: sex, age, age at diagnosis 
of T1D and duration of T1D until entry into the Biobank 
database (controls) or until the transplant or renal replacement 
therapy (cases). Hp genotyping was carried out using samples 
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and 33.4 % in controls; P=.8) or a protective effect of the 
genotype 1-1 (19.3 % in cases and 17.5 % in controls; P=.8).
Our study is not without its limitations. Given that our 
cases had very restricted selection criteria, our sample of 
patients with T1D is limited. In addition, we do not know the 
longitudinal information about the metabolic control or other 
confounding factors that could influence the evolution of DN, 
such as smoking or hypertension.
In conclusion, in our sample of Spanish patients with 
T1D, the genotype of Hp did not appear to have an 
implication for the risk of DN. In light of our results and 
the contradictory results from other studies, more studies 
are needed, with a wider sample group and of prospective 
nature, in order to clarify the role of Hp in the risk of 
microvascular complications in T1D.
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